A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors.
Alov P, Al Sharif M, Aluani D, Chegaev K, Dinic J, Divac Rankov A, Fernandes MX, Fusi F, García-Sosa AT, Juvonen R, Kondeva-Burdina M, Padrón JM, Pajeva I, Pencheva T, Puerta A, Raunio H, Riganti C, Tsakovska I, Tzankova V, Yordanov Y, Saponara S.
Alov P, et al. Among authors: juvonen r.
Front Pharmacol. 2022 Mar 7;13:831791. doi: 10.3389/fphar.2022.831791. eCollection 2022.
Front Pharmacol. 2022.
PMID: 35321325
Free PMC article.